Clinical Trial Details
— Status: Active, not recruiting
Administrative data
NCT number |
NCT06364254 |
Other study ID # |
2311054791 |
Secondary ID |
|
Status |
Active, not recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
November 11, 2023 |
Est. completion date |
May 30, 2024 |
Study information
Verified date |
May 2024 |
Source |
University of Northern Colorado |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Individuals who engage in endurance events tend to experience higher levels of stress within
the body, mind, and gut, that often lead to impairment of performance. Based on previous
studies, CBD has the potential relieve gut distress, and reduce pre-race anxiety thus
resulting in an improvement in sport performance. Given the current research on the use of
CBD in active individuals, the aim of this pilot study is to explore the effects of CBD
compared to a placebo on anxiety, GI distress and a 2-mile running performance in a
moderately active population identifying as female.
Description:
This study will recruit moderately active, healthy individuals (N=30) who identify as female
between the ages of 18-40 years who have some running experience and are running at least 2
miles, 2 times per week. This will be a cross over study, so each participant will be their
own control, receiving either the placebo and CBD on two separate occasions. The females
recruited will report to the Exercise Physiology lab in Gunter Hall on the University of
Northern Colorado's campus for testing a total of two times.
The first visit will include initial paperwork such as the informed consent, physical
activity readiness questionnaire (PARQ), Menstrual Cycle Questionnaire and a screening to
determine current activity levels, uses CBD, THC and any other legal drugs/medications. This
first interaction allows study staff to ensure that qualify to take part in the study.
After informed consent is obtained, the participant will be given either the placebo or CBD
capsule with a controlled higher fat food (88 Acres protein bar) 2 hours before the testing
protocol along. Once the CBD capsule or placebo is taken, participants will complete caffeine
consumption, exercise and running questionnaires which will be administered on a tablet with
study staff after 1.5 hours or waiting.
During the first visit, individuals will stay for a standardized period (2 hours) before
doing a urine analysis to determine hydration status and taking v lactate, and heart rate
variability. Current anxiety symptoms will also be evaluated
Once baseline measurements obtained, individuals will then be instructed to run 2 miles a
treadmill as fast as possible. Lactate will be monitored three times during the test (.50
mile mark, halfway point (1 mile) and just before finishing the time trial run at the 1.98
mile mark). All participants will be taken through a 30-minute cool down period walking 2.5
mph on the treadmill while having lactate measured every 5, 10, 15, and 30 minutes post
finishing. Finish time, GI distress questionnaire, and overall feelings will be recorded post
finish of the 2 mile time trial.
Participants will be given a 25-30 day time between visits 1 and 2 to ensure exercise during
the same menstrual cycle phase (hormone cycle) for those that are cycling. During the second
and final visit, participants will undergo the same procedure, however, will be given the
opposite oral administration from the first visit (either placebo or CBD).